MiNK Therapeutics, Inc.INKTNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank33
3Y CAGR-28.6%
5Y CAGR+0.9%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-28.6%/yr
Annual compound
5Y CAGR
+0.9%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$11.23M+7.6%
2024$10.43M-54.1%
2023$22.72M-26.3%
2022$30.83M+66.4%
2021$18.53M+72.5%
2020$10.74M-53.2%
2019$22.97M-